Market Place
Sourcing Support
Vaccinex Updates SIGNAL-AD Phase 1b/2 Trial Findings For Alzheimer`s Disease
14 Aug 2024 //
GLOBENEWSWIRE
Vaccinex To Present Alzheimer`s Trial Data At AAIC On July 31
17 Jul 2024 //
GLOBENEWSWIRE
Vaccinex Announces $3.8 Million Private Placement
28 Nov 2022 //
GLOBENEWSWIRE
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Vaccinex and its Collaborators Present Two Abstracts to Pepinemab Combination
10 Nov 2022 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update
15 Aug 2022 //
GLOBENEWSWIRE
Vaccinex’s PII “SIGNAL” Study to Evaluate Pepinemab Ab in Huntington’s Disease
08 Aug 2022 //
GLOBENEWSWIRE
Vaccinex to Present at the 2022 AAIC Updating the SIGNAL-AD Study of Pepinemab
29 Jul 2022 //
GLOBENEWSWIRE
Vaccinex to Participate in the Jefferies Healthcare Conference
25 May 2022 //
GLOBENEWSWIRE
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
16 May 2022 //
GLOBENEWSWIRE
Vaccinex, Announces Upcoming Presentation at the PEGS Boston Conference & Expo
25 Apr 2022 //
GLOBENEWSWIRE
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
31 Mar 2022 //
GLOBENEWSWIRE
Vaccinex Reports positive interim response data in Phase Ib of KEYNOTE-B84 study
26 Jan 2022 //
GLOBENEWSWIRE
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda & Pepinemab
04 Jan 2022 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC)
10 Nov 2021 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD)
09 Nov 2021 //
GLOBENEWSWIRE
Vaccinex Reports 3Q2021 Financial Results and Provides Corporate Update
08 Nov 2021 //
GLOBENEWSWIRE
Vaccinex to Present at the Virtual Huntington’s Study Group on Nov4-6, 2021
01 Nov 2021 //
GLOBENEWSWIRE
Vaccinex to Present at Oppenheimer Fall Healthcare Summit
17 Sep 2021 //
GLOBENEWSWIRE
Vaccinex CEO Presented New and Promising Phase 2 SIGNAL Trial Data
15 Sep 2021 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Vaccinex to Chair Panel Q&A Session & Present Poster at the XV European Meeting
30 Jun 2021 //
GLOBENEWSWIRE
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2
21 Apr 2021 //
VACCINEX
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
22 Feb 2021 //
GLOBENEWSWIRE
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study
29 Oct 2020 //
GLOBENEWSWIRE
Vaccinex`s drug misses the mark in Huntington phII; focus shifts to Alzheimer`s
22 Sep 2020 //
FIERCE BIOTECH
Vaccinex Provides Update of Potentially Pivotal SIGNAL Trial in Huntington’s
07 Jul 2020 //
GLOBENEWSWIRE
Vaccinex to Present Updated Results from Ph1b/2 Study of Pepinemab (VX15/2503)
13 May 2020 //
GLOBENEWSWIRE
Updated Interim Results from CLASSICAL-Lung, Ph1b/2 Study of (VX15/2503)
27 Apr 2020 //
VACCINEX
Vaccinex Delivers Virtual Presentation at the in Alzheimer’s and Parkinson
07 Apr 2020 //
GLOBENEWSWIRE
Vaccinex joins coronavirus-stoked rally
24 Jan 2020 //
SEEKING ALPHA
